FAP-targeted chimeric antigen receptor (CAR) T cells have shown promise in preclinical models by remodeling the tumor stroma and enhancing immune responses, with early clinical trials indicating acceptable safety [153,154,155,156,157]. The gene discussed is FAP; the disease is neoplasm.